Oliver Engert Acquires 5,140 Shares of Enovis (NYSE:ENOV) Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert purchased 5,140 shares of Enovis stock in a transaction on Thursday, September 3rd. The stock was bought at an average price of $19.46 per share, for a total transaction of $100,024.40. Following the completion of the acquisition, the insider owned 61,238 shares in the company, valued at $1,191,691.48. The trade was a 9.16% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Oliver Engert also recently made the following trade(s):

• On Wednesday, September 2nd, Oliver Engert acquired 2,458 shares of Enovis stock. The shares were bought at an average cost of $20.32 per share, with a total value of $49,946.56.
• On Monday, June 15th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were purchased at an average price of $20.92 per share, with a total value of $20,920.00.
• On Thursday, June 11th, Oliver Engert bought 1,200 shares of Enovis stock. The stock was purchased at an average cost of $21.62 per share, for a total transaction of $25,944.00.
• On Wednesday, June 10th, Oliver Engert bought 1,000 shares of Enovis stock. The stock was purchased at an average price of $23.00 per share, for a total transaction of $23,000.00.

Enovis Price Performance

Shares of Enovis stock opened at $18.58 on Friday. The stock has a 50 day moving average of $25.50 and a 200 day moving average of $24.20. Enovis Corporation has a 12 month low of $18.52 and a 12 month high of $34.28. The firm has a market cap of $1.07 billion, a PE ratio of -0.96 and a beta of 1.31. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. The business had revenue of $582.78 million for the quarter, compared to the consensus estimate of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts expect that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ENOV. Arax Advisory Partners purchased a new stake in shares of Enovis in the fourth quarter valued at $29,000. Allworth Financial LP bought a new position in Enovis during the 2nd quarter valued at about $36,000. EverSource Wealth Advisors LLC raised its position in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. Public Employees Retirement System of Ohio bought a new stake in Enovis in the second quarter worth about $48,000. Finally, Danske Bank A S purchased a new position in shares of Enovis during the third quarter valued at approximately $64,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on ENOV shares. UBS Group reiterated a “buy” rating and set a $51.00 price objective (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Wells Fargo & Company reduced their target price on shares of Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday. Wall Street Zen cut shares of Enovis from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Finally, Citigroup reiterated a “market outperform” rating on shares of Enovis in a research report on Wednesday. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $40.38.

Trending Headlines about Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
• Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
• Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
• Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
• Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
• Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.